Alcon touts PhIII win for dry eye drug, plans mid-2024 FDA filing
10 Jan 2024
Phase 3Clinical Result
Alcon is looking to file its top clinical candidate for FDA approval mid-year after clinching positive Phase III results.
Its eye drop candidate, AR-15512, helped more people with dry eye disease boost their tear production at day 14 than placebo. Although the company didn’t spell out the proportions of participants who saw at least a 10-mm increase in unanesthetized Schirmer’s score — measuring tear production with a paper strip — Alcon said the difference was statistically significant (p
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.